We advised Nanoform Finland Oy on their SEK 71 million private placement where Vator Securities AB acted as the sole bookrunner and Mandatum Life Insurance Company (Sampo Group) as the anchor investor.
Every year only 30–60 drugs are approved by regulatory authorities. Failures in trials can cost up to EUR 50 billion. Nanoform can give failed drug molecules a second chance by providing groundbreaking services in nanotechnology and drug particle engineering for the international pharma industry. Nanoform’s proprietary technology, Controlled Expansion of Supercritical Solutions (CESS) is a tested and proven method whereby nanonisation (the process of shrinking drug particles without changing their chemical properties) takes place. The company has already successfully nanonised several active pharmaceutical ingredients (APIs). The process is more controlled than conventional supercritical technologies and can produce smaller and more uniformly sized particles in an industry where particle size is critical. An aging global population increases the demand for new drugs, ensuring a rapidly growing addressable market.
Having advised Nanoform and its founders since the technology was first developed, we are honoured to have assisted Nanoform in taking this successful next step to expand its business. The private placement, directed at Swedish and Finnish investors, is also a great example of the opportunities available in the Nordic market.